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Abstract 
Background: Epilepsy is one of the most common neurological diseases characterized by excessive hyperexcitability 
of neurons. Molecular mechanisms of epilepsy are diverse and not really understood. All in common is the misregula-
tion of proteins that determine excitability such as potassium and sodium channels as well as GABA receptors; which 
are all known as biomarkers for epilepsy. Two recently identified key pathways involve the kinases mechanistic target 
of rapamycin (mTOR) and mitogen-activated protein kinases (MAPK). Interestingly, mRNAs coding for those biomark-
ers are found to be localized at or near synapses indicating a local misregulation of synthesis and activity.
Results: Research in the last decade indicates that RNA-binding proteins (RBPs) responsible for mRNA localiza-
tion, stability and translation mediate local expression control. Among others, they are affected by mTOR and MAPK 
to guide expression of epileptic factors. These results suggest that mTOR/MAPK act on RBPs to regulate the fate of 
mRNAs, indicating a misregulation of protein expression at synapses in epilepsy.
Conclusion: We propose that mTOR and MAPK regulate RBPs, thereby guiding the local expression of their target-
mRNAs encoding for markers of epilepsy. Thus, misregulated mTOR/MAPK-RBP interplay may result in excessive local 
synthesis of ion channels and receptors thereby leading to hyperexcitability. Continuous stimulation of synapses 
further activates mTOR/MAPK pathway reinforcing their effect on RBP-mediated expression control establishing the 
basis for epilepsy. Here, we highlight findings showing the tight interplay between mTOR as well as MAPK with RBPs 
to control expression for epileptic biomarkers.
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Background
Epilepsy is one of the most common neurological dis-
eases, affecting about 65 million people in the world 
[1], therein 8.5 per 1000 population in the US [2] and 18 
per 1000 population in Europe [3]. The disease affects 
life quality through discrimination and segregation of 
patients [4]. Furthermore, therapies have high economic 
costs of up to $13.8 billion in Europe [5]. Available thera-
pies usually target symptoms and are still ineffective in 
30% of all cases [6]. It is commonly believed that abnor-
mal synchronous firing in a hyperexcitable neuronal 
network results in epileptic seizures [7]. Generally, epi-
lepsy can be differentiated according to the region of its 
generation: Generalized seizures origin from both hemi-
spheres, whereas focal epilepsy derives from one specific 
area of the brain, most commonly the temporal lobe or 
the limbic system, which results in temporal lobe epi-
lepsy (TLE) [8]. Idiopathic epilepsies that can take both 
generalized and focal forms, have a genetic or epige-
netic cause, classifying genetic epilepsy as one specific 
group [9]. In the last decade, immense effort was made 
to identify mutations ending up with a list of genetic 
risk factors causing epilepsy [10, 11] (Table 1). In 40% of 
the cases, however, the etiology of epilepsy is unknown. 
This emphasizes the need for a better understanding of 
genetic causes forming the basis of putative therapies.
The genetic risk factors that have been found are 
diverse and are involved in regulation of various pathways 
affecting cell death, morphology and neurogenesis. One 
aspect that is essential for all models of epileptogenesis is 
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the dysregulation of synaptic function. This includes pre-
synaptic vesicle release, postsynaptic receptor expression 
and ion channel expression, which have provided new 
approaches on therapy for epilepsy [12, 13].
Recently, it has been shown that the mechanistic tar-
get of rapamycin (mTOR) and mitogen-activated protein 
kinases (MAPK) are important regulators of synaptic 
excitability involved in cognitive impairment and epilepsy 
in animal models as well as human disease [14–16]. Those 
kinases regulate gene expression in neurons in a stimu-
lus-dependent manner [17, 18]. Both pathways can be 
activated i.e. by long-term potentiation (LTP), a process 
characterized by enhanced transmission between simulta-
neously activated synapses. Still, not all neuronal stimula-
tion paradigms lead to the activation of both mTOR and 
MAPK pathways [19, 20]. Further research is necessary to 
describe the exact mechanisms and kind of neuronal exci-
tation that leads to hyperactivity. Regardless, multiple key 
studies show an effect of mTOR and MAPK on general 
expression control [21, 22]. Remarkably, recent research 
has shown that both mTOR and MAPK also act locally 
to regulate protein expression at activated synapses [17, 
22]. Together, these findings provide new insight into the 
molecular mechanisms of epilepsy and explain how lack 
of pathway control results in seizures.
RNA‑binding proteins: mediators of remote 
expression control
Research in the last decade has shown that RNA-binding 
proteins (RBPs) are essential regulators of protein expres-
sion. For local gene expression, it was shown that RBPs 
regulate gene expression in a spatially restricted man-
ner. mRNAs sequester RBPs by binding motifs in their 
3′-untranslated region (3′-UTR). 3′-UTRs of localized 
transcripts are generally longer and more complex har-
boring cis-acting sequence motifs and secondary struc-
tures as binding platforms. It is commonly believed that 
some RBPs form large RNA–protein complexes termed 
RNA granules. These granules are transported along the 
cytoskeleton to synapses [23]. Upon stimulation, those 
particles are unpacked, the mRNA is released and locally 
translated. The process of remote expression control is 
mediated by RBPs. They control different steps of post-
transcriptional regulation such as mRNA transport, trans-
lation and mRNA stability (reviewed in [24, 25]). The 
synchronization of all three steps is a prerequisite for local 
protein expression. Therefore, translation regulators such 
as Pumilio2 (Pum2) are part of transport granules as it was 
shown for Staufen2 (Stau2) [26]. The relevance of RBPs 
for the occurrence of neurological and neuropsychiatric 
diseases has risen in the last years. Both loss of function 
and gain of function mutations of RBPs result in epileptic 
phenotypes [27–29]. There is evidence that known epi-
lepsy targets are under control of RBPs suggesting a local 
expression control of those mRNAs; probably at synapses. 
RBPs regulate mRNA distribution and protein synthesis 
of known epilepsy targets such as CaMKIIα or KCNA1 
encoding for the potassium channel Kv1.1, as well as mul-
tiple other ion channels [30]. It is therefore tempting to 
postulate that any aberrant translational control of newly 
synthesized proteins for regulators of synaptic excitability, 
e.g. ion channels or receptors, leads to epilepsy.
Table 1 Epilepsy targets that are regulated by RBPs and dependent on mTOR/MAPK activity
RBPs, their general effect on gene expression, involvement in mTOR and/or MAPK pathways, their mRNA targets, and encoded proteins as well as their link to epilepsy 
in animal models and human patients are depicted
Effect Pathway Epilepsy related targets Link to epilepsy
Gene Protein
FMRP Translational repression and dendritic RNA 
transport [48]
mTOR [57–61] CaMKIIα CaMKIIα [20, 48] Childhood seizures in patients and mice with 
FXS [27, 56]MAPK [20, 62, 65] KCNC1 Kv3.1 [52]
KCND2 Kv4.2 [54]
CACNA1B Cav2.2 [53] Audiogenic seizures in rats with FXS [62]
KCNMA1 BK channel [51]
KCNT1 Slack channel [50]
HuD RNA stabilization mTOR [76, 77, 79] CaMKIIα CaMKIIα [77] Increased protein level in rats with kainate 
induced seizures [70]Splicing control MAPK [76, 80] KCNA1 Kv1.1 [69]
Neuronal differentiation and plasticity [67] GLS Glutaminase [73] Increased susceptibility to audiogenic  
seizures in mice [28]
HuR RNA stabilization MAPK [82–85] GAP-43 GAP-43 [68, 72] Pentylenetetrazol-induced seizures in mice 
[82]Splicing control [86]
Cellular stress response [67]
CREB Translational activator [89] MAPK [40] Bdnf BDNF [29, 92] Epileptic seizures in animal models of  
epilepsy and human patients [29]
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Dysregulation of mTOR‑mediated expression 
control leads to epileptic seizures
mTOR is a serine-threonine kinase that forms two pro-
tein complexes termed mTORC1 and mTORC2 [31]. 
mTORC1 consists of five components: mTOR as active 
center, raptor, MLST8, PRAS40 and DEPTOR. It is gen-
erally believed that mTOR acts mainly on translation. As 
a central check point, mTORC1 senses both internal and 
external signals such as nutrient and growth factor avail-
ability as well as oxidative stress to guide protein syn-
thesis. mTORC2 is a rapamycin insensitive complex that 
contributes to cell survival functions, metabolism, pro-
liferation and actin polymerization [31]. The exact role 
of mTORC2 in cellular signaling is still unclear. Several 
neuropathological diseases such as autism, depression 
and epilepsy have been linked to dysregulation of both 
complexes [17].
mTOR is a major player in the generation of neuronal 
homeostasis. Important factors for its maintenance is 
the balance of GABAergic and glutamatergic signaling, 
both of which are regulated by mTOR signaling [32]. Ele-
vated activity of mTORC1 is implicated with increased 
neuronal excitability [31]. The relevance of mTOR 
regarding temporal lobe epilepsy in animal models and 
patients has been rising in importance throughout the 
last decade [33–35]. Various genetic diseases display-
ing a grave epileptic phenotype, like tuberous sclerosis, 
phosphatase and tensine homolog (PTEN)-hamartoma 
tumor syndromes and fragile X mental retardation syn-
drome (FXS), are associated with dysregulation of mTOR 
expression and activity [17]. Specifically, excessive mTOR 
signaling through a mutation in the tuberous sclerosis 
complex (TSC1/2) leads to hippocampal hyperexcit-
ability linking mTOR with temporal lobe epilepsy [36]. 
Seizures generated in the hippocampus have also been 
related to hyperactive mTOR signaling in a mouse model 
harboring PTEN mutations. Knock-out of PTEN leads 
to hyperactive mTOR causing seizures generated in the 
hippocampus, mimicking the epileptic phenotype of 
focal cortical dysplasia [37]. Thus, controllability of excit-
ability by mTOR is crucial to maintain balanced firing of 
neurons.
Expression control by the MAPK pathway: a 
regulator of epileptic biomarkers
The mitogen-activated protein kinase (MAPK) family 
consists of three pathways, the extracellular signal regu-
lated kinase (ERK) pathway, the p38 pathway and C-Jun 
N-terminal kinases (JNK) pathway. All three are highly 
conserved serine-threonine kinases that respond to 
nutrition and growth factors availability as well as neu-
ronal activation [38]. ERK stimulates the expression of 
N-methyl-d-aspartate (NMDA) receptors causing synap-
tic excitability. This, in turn, leads to seizures [38]. More-
over, the neuroprotective effect of NMDA injected in 
mice before seizure induction is diminished by inhibition 
of the MAPK pathway, further underlining the poten-
tial of MAPK to regulate neuronal excitability [39]. Also 
the induction of mossy fiber sprouting, an effect causally 
associated with epileptogenesis, by the ERK/MAPK path-
way has been shown in rats after traumatic brain injury 
[40]. This further supports a role of MAPK pathway in 
epileptogenesis. Interestingly, MAPK responds to differ-
ent seizures-inducing treatments: maximal electroshock 
seizures in mice [41], kainate [42], pilocarpine [43] and 
pentylenetetrazole [44] as well as dopamine D1 recep-
tor (D1R) agonist [45]. These findings suggest a role of 
MAPK in epileptogenesis.
Strikingly, there is evidence that also the MAPK path-
way involves RBPs that are misregulated in epilepsy, like 
FMRP and HuR. In this context, kinases regulate those 
proteins and, therewith, their ability to control posttran-
scriptional gene expression [22, 46].
mTOR and MAPK pathways control RBPs 
and thereby protein expression
Some of the RBPs mentioned above are guided by 
mTOR/MAPK. Thus, it has been suggested that mTOR/
MAPK affect local gene expression by regulating RBPs. 
In this review, we will focus on the effect of mTOR and 
MAPK on RBPs linking local expression control with 
neuronal hyperexcitability in epilepsy. We focus on local-
ized transcripts at or near synapses that encode for pro-
teins causing epilepsy. In addition, we emphasize that 
RBPs (1) regulate expression of those epilepsy targets 
and (2) are involved in the mTOR and/or MAPK path-
way (Fig. 1). Together, mTOR/MAPK mediated control of 
RBPs represent a novel mechanism of remote expression 
control. In the following paragraphs, we will focus on 
RBPs already shown to be regulated by the mTOR and/or 
MAPK pathway.
FMRP
Mutations in the fragile X mental retardation gene (fmr1) 
coding for the translation regulator FMRP lead to activ-
ity-dependent misregulation of protein synthesis at syn-
apses and can result in seizures [27]. FMRP is an RBP 
involved in dendritic transport and translation control 
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[47], specifically as a translational repressor [48]. It reg-
ulates the synthesis of calcium/calmodulin dependent 
protein kinase II alpha (CaMKIIα) that influences syn-
aptic plasticity [49], the expression of multiple ion chan-
nels [50–54] and can lead causes epilepsy in knock-out 
mutant mice [55].
FMRP loss of function causes fragile X syndrome (FXS). 
Interestingly, FXS patients also suffer from seizures [56]. 
Furthermore, there is supportive evidence for a role of 
FMRP in temporal lobe epilepsy: In patients with tem-
poral lobe epilepsy and in rats treated with the seizure-
inducing drug pilocarpine, the level of cytosolic FMRP 
binding protein (CYFIP1) is elevated [57]. CYFIP is a 
protein expressed at synapses, displaying multiple func-
tions like local regulation of actin cytoskeleton dynamics 
and dendritic spine morphology [57]. Interestingly, mor-
phological abnormalities resulting from overexpressed 
CYFP1 can be rescued by the mTOR inhibitor rapa-
mycin [58] linking mTOR activity with a direct FMRP 
interactor. Furthermore, it has been shown that ele-
vated levels of phosphorylated mTOR is associated with 
decreased FMRP [59]. Additionally, regulation of FMRP 
via the mTOR target p70-S6 kinase (S6K1) has been pro-
posed [60]. S6K1 phosphorylates FMRP and, thereby, it 
regulates its ability to repress translation. Surprisingly, 
the phosphorylation of FMRP has been reported to be 
mTOR independent [61] indicating an indirect effect of 
mTOR on FMRP-mediated expression control. Together, 
these results suggest that FMRP and mTOR are influenc-
ing each other to fine-tune protein expression.
The MAPK pathway is generally activated upon neu-
ron stimulation. Activation of glutamate receptors, i.e. 
NMDA receptors, plays an important role in the gen-
eration of hyperactive firing of neurons. In this respect, 
activation of the metabotropic glutamate receptor 5 
(mGluR5) results in excessive protein production in fmr1 
knockdown mice [20]. Interestingly, young FXS rats are 
susceptible to audiogenic seizures [62]. One hypothesis 
Fig. 1 Venn diagram showing mTOR/MAPK mediated expression control via RBPs. Localized RNAs encoding for proteins involved in epilepsy are 
regulated by RBPs. Those, in turn, are guided by mTOR/MAPK
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states that elevated protein levels at synapses leads to 
seizures [27, 63]. In contrast, mGluR5 does not directly 
influence chemically induced epilepsy in rats [64]. Inhibi-
tion of mGluR5 corrects symptoms of fragile X syndrome 
in adult mice and, importantly, reduces overactive ERK 
and mTOR signaling [65]. Furthermore, a direct link has 
been suggested from mGluR5 activation to mTOR and 
MAPK pathways in modulating FMRP-mediated expres-
sion control [66]. Importantly, the fragile X syndrome 
phenotype can be reversed by blocking ERK activity sug-
gesting an interplay between FMRP and the ERK path-
way [20, 62]. Since FXS-patient also suffer from seizures, 
those results indicate also a possible link to epilepsy.
Hu protein family
Another group of RBPs connected to neurological disease 
is the Hu protein family (reviewed in [67]). Hu proteins 
are related to the embryonic lethal abnormal vision pro-
tein family (Elav) and were first described in patients with 
paraneoplastic encephalomyelitis [68]. These proteins 
are primarily responsible for neuronal differentiation, 
learning and memory, as well as long-term potentiation. 
They exert their RNA stabilizing function via three highly 
conserved RNA recognition motifs binding to AU-rich 
regions in the 3′-UTR, in the polyA tail [68] and in the 
coding region [69].
One member of the Hu family is HuD that regu-
lates gene expression in neurons. HuD is upregulated 
after kainate-induced seizures in rats and shows activ-
ity dependent increase in protein levels in hippocam-
pal neurons [70, 71]. Additionally, HuD localizes in an 
activity dependent manner in dendrites and interacts 
with mTOR targets in KCl stimulated hippocampal 
neurons [72]. DeBoer et al. showed that HuD knockout 
mice also show increased susceptibility to auditory sei-
zures [28]. Supportive for these findings are results from 
other groups indicating a role of HuD in the regulation 
of synaptic excitability by adjusting the cellular gluta-
mate levels via translation control of the glutaminase 
[73]. Unbalanced glutamate levels and related recep-
tors are responsible for epileptogenesis [74]. Work 
by Sosanya et  al. indicates an antagonistic relation-
ship between HuD and mTOR in regulating expres-
sion of the voltage-gated potassium channel 1.1 (Kv1.1) 
expression [69]. mTOR inhibition leads to degradation 
of HuD targets thereby increasing the concentration 
of free HuD molecules that are binding Kv1.1 mRNA 
more efficiently. Hence, Kv1.1 expression is increased 
upon mTOR-inhibition [21, 69]. Low Kv1.1 levels are 
associated with increasing seizure frequency in kainate 
induced temporal lobe epilepsy in rats, correlating with 
high mTOR levels [75].
HuD has been shown to control changes in synaptic 
plasticity via the local translation of synaptic proteins 
such as CaMKIIα [76]. Recent reports point to the 
interplay of the mTOR pathway with HuD-mediated 
expression control guiding branch specific expression of 
CaMKIIα [77]. Proper cellular and subcellular expres-
sion of CaMKIIα is crucial for neuronal excitability. 
Consequently, dysfunctions might contribute to epi-
lepsy [78].
Importantly, inhibition of the protein kinase B (Akt)/
glycogen synthase kinase 3 (GSK3) pathway leads 
to changes in HuD and HuR protein levels [76]. The 
GSK3 pathway therefore represents a link between the 
mTOR, Akt and MAPK pathways [79]. This suggests an 
interplay in the control of HuD between the different 
kinases. Together, these findings indicate that mTOR is 
necessary to guide HuD-mediated expression control. 
CaMKIIα, Kv1.1 and glutaminase mRNAs are known 
HuD targets influencing neuronal excitability. Disrup-
tion of HuD expression control results in hyperactivity 
and seizures.
Additionally, neuronal activity causes HuD to localize 
in dendrites and dendritic spine like protrusions in pri-
mary hippocampal neurons [76]. Furthermore, it colo-
calizes with the eukaryotic translation initiation factor 
4E (eIF4E) suggesting regulation of translation. Known 
as a target of mTOR mediated translation activation via 
4E-binding protein (4EBP), elF4E is a point of conver-
gence between the mTOR and the MAPK pathway. This 
was observed in mGluR dependent LTP. Activation of 
mGluR leads to ERK2 activation, which further phospho-
rylates and activates MAPK interacting kinase 2 (Mnk2) 
leading to eIF4E phosphorylation [80]. mGluR activa-
tion also recruits the phosphoinositide 3-kinase (PI3K)/
mTOR pathway [81], releasing the 4E binding protein 2 
(4EBP2) mediated inhibition of elF4E and promoting 
translation [80].
HuR is another well-studied member of the Hu fam-
ily and ubiquitously expressed. Activation of the MAPK 
pathway by anisomycin causes stabilization of sur-
vival motor neuron (SMN) mRNA by HuR [82]. Fur-
thermore, several studies reveal the MAPK pathway 
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to regulate HuR [82–84]. In a mouse pentylenetetra-
zole model of epilepsy, HuR target mRNAs in the hip-
pocampus were analyzed [85]. Amongst them were 
identified genes encoding for mossy fiber sprouting 
and apoptosis, which contribute to epilepsy [85]. In 
addition, GAP-43 encoding for homonymous protein 
involved in axon growth is bound [86] and stabilized by 
HuR [76]. Importantly, GAP-43 is a marker for progres-
sive epilepsy in patients with focal cortical dysplasia 
[87].
CREB
cAMP response element binding protein (CREB) is a 
transcription activator [88]. It has been shown that it 
is crucial for the induction of LTP [89]. In a genome-
wide microarray analysis of hippocampal tissue from 
patients with temporal lobe epilepsy, the protein kinase 
A (PKA)/CREB pathway appeared as one of the most 
enriched [90]. In addition, activation of CREB appears 
to cause epilepsy in rodent and human models [29]. 
Furthermore, CREB-regulated transcription coacti-
vator 1 (CRTC1) has been shown to translocate into 
hippocampal nuclei following pilocarpine-induced 
status epilepticus [91]. CREB does not only influence 
transcription in the nucleus, but also leads to cell wide 
supply of protein and mRNA that can localize to the 
synapse when the synapse has been tagged, thereby 
permitting LTP [88, 89]. One transcript targeted by 
CREB is the brain derived neurotrophic factor (BDNF) 
[92], which has been associated to temporal lobe epi-
lepsy in many cases [93] and may serve as a serum 
marker for epilepsy [94].
It is interesting to note that the MAPK pathway is a 
known regulator of CREB [40, 95]. Furthermore, the 
MAPK-CREB pathway induces mossy fiber reorganiza-
tion after traumatic brain injury in rats, a characteristic 
feature of epileptogenesis [40]. In the human neocor-
tex of epilepsy patients, a specific ERK activation pat-
tern was linked to CREB phosphorylation and followed 
by enhanced transcription of CREB targets such as 
BDNF [96]. Additionally, increased synaptic density was 
observed in these layers linking synaptic morphology 
with CREB-induced BDNF transcription. Interestingly, it 
has been shown that BDNF induces synthesis of the early 
growth response factor 3 (EGR3) which regulates GABA 
receptors indicating a role of CREB in neuronal excitabil-
ity [96]. These results highlight the causal link of MAPK 
activation and its effect on RBP-mediated expression 
control.
Conclusions
It is generally believed that epilepsy results from hyper-
excitability and synchronous firing of neurons [7]. In the 
last decade, many biomarkers such as potassium and 
sodium channels as well as GABA receptors have been 
identified (Table  1). Beside those, mTOR and MAPK 
also contribute to epileptogenesis. Very often they are 
key players of converging pathways. Nonetheless, the 
underlying molecular mechanism of hyperexcitability 
and, in consequence, synchronous firing remain elusive. 
Strikingly, it has been shown that transcripts encoding 
for some of epileptic biomarkers including mTOR are 
localized in dendrites. Additionally, RBPs, mediators of 
RNA localization and remote expression control, have 
been linked to epilepsy bridging mTOR signaling with 
spatially restricted expression. We propose that hyper-
active mTOR and MAPK affect RBPs and RBP-mediated 
expression control locally (Fig.  2). Thereby, they influ-
ence transcript transport, stability and translation at or 
near synapses of RBP target mRNAs. Thus, increased, 
local expression of ion channels and receptors results in 
enhanced synaptic density of excitability regulating pro-
teins and, eventually, in increased synaptic transmission. 
In turn, augmented synaptic stimulation further activates 
mTOR and MAPK. This spatially restricted misregula-
tion of synaptic excitability may therefore represent an 
accelerator of synchronous, neuronal firing that even-
tually results in seizures. Thus, RBPs might represent 
a novel category of epileptic biomarkers that can help 
to diagnose epilepsy in patients. Furthermore, they also 
can serve as additional targets for therapeutics. However, 
future studies will elucidate their eligibility for diagnosis 
and therapy.
In conclusion, remote expression control that is regu-
lated by mTOR and MAPK provides new approaches 
to understand epilepsy at a molecular and cellular level. 
Here, mTOR possibly regulates RBPs, i.e. via direct phos-
phorylation, to guide their expression control abilities. 
This regulation of RBPs via mTOR may be affected by 
inhibiting drugs such as Rapamycin. A recent phase 3 
study on Everolimus, a Rapamycin analog, shows a posi-
tive effect on therapy resistant focal epilepsy related to 
tuberous sclerosis [97]. This points to a significant role of 
mTOR inhibitors in epilepsy, and suggests a potential for 
the therapy of epilepsy caused by RBP deficiency. Never-
theless, more insight is necessary to develop new diag-
nosis and therapy strategies for the treatment of epilepsy 
and to understand side effects of mTOR and MAPK inhi-
bition [98].
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